PortalPublikationenUpper-Urinary-Tract Effects After Irreversible Electroporati...

Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study

Standard

Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study. / Wendler, J J; Pech, M; Köllermann, J; Friebe, B; Siedentopf, S; Blaschke, S; Schindele, D; Porsch, M; Baumunk, D; Jürgens, J; Fischbach, F; Ricke, J; Schostak, M; Böhm, M; Liehr, U B.

in: CARDIOVASC INTER RAD, Jahrgang 41, Nr. 3, 03.2018, S. 466-476.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wendler, JJ, Pech, M, Köllermann, J, Friebe, B, Siedentopf, S, Blaschke, S, Schindele, D, Porsch, M, Baumunk, D, Jürgens, J, Fischbach, F, Ricke, J, Schostak, M, Böhm, M & Liehr, UB 2018, 'Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study', CARDIOVASC INTER RAD, Jg. 41, Nr. 3, S. 466-476. https://doi.org/10.1007/s00270-017-1795-x

APA

Wendler, J. J., Pech, M., Köllermann, J., Friebe, B., Siedentopf, S., Blaschke, S., Schindele, D., Porsch, M., Baumunk, D., Jürgens, J., Fischbach, F., Ricke, J., Schostak, M., Böhm, M., & Liehr, U. B. (2018). Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study. CARDIOVASC INTER RAD, 41(3), 466-476. https://doi.org/10.1007/s00270-017-1795-x

Vancouver

Wendler JJ, Pech M, Köllermann J, Friebe B, Siedentopf S, Blaschke S et al. Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study. CARDIOVASC INTER RAD. 2018 Mär;41(3):466-476. https://doi.org/10.1007/s00270-017-1795-x

Bibtex

@article{9687c53bf86e43b9aca95d0732093ea4,
title = "Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study",
abstract = "PURPOSE: Irreversible electroporation (IRE) is a new potential ablation modality for small renal masses. Animal experiments have shown preservation of the urine-collecting system (UCS). The purpose of this clinical study was to perform the first evaluation and comparison of IRE's effects on the renal UCS by using urinary cytology, magnetic-resonance imaging, and resection histology in men after IRE of pT1a renal-cell carcinoma (RCC).METHODS: Seven patients with biopsy-proven RCC pT1a cN0cM0 underwent IRE in a phase 2a pilot ablate-and-resect study (IRENE trial). A contrast-enhanced, diffusion-weighted MRI and urinary cytology was performed 1 day before and 2, 7, and 27 days after IRE. Twenty-eight days after IRE the tumour region was completely resected surgically.RESULTS: Technical feasibility was demonstrated in all patients. In all cases, MRI revealed complete coverage of the tumour area by the ablation zone with degenerative change. The urographic late venous MRI phase (urogram scans) demonstrated normal morphological appearances. Urine cytology showed a temporary vacuolisation of the cyto- and caryoplasmas after IRE. Whereas the urothelium showed signs of regeneration 28 days after IRE-ablation, the tumour and parenchyma below it showed necrosis and permanent tissue destruction.CONCLUSIONS: Renal percutaneous IRE appears to be a safe treatment for pT1a RCC. The preservation of the UCS with unaltered normal morphology as well as urothelial regeneration and a phenomenon (new in urinary cytology) of temporary degeneration with vacuolisation of detached transitional epithelium cells were demonstrated in this clinical pilot study.",
keywords = "Journal Article",
author = "Wendler, {J J} and M Pech and J K{\"o}llermann and B Friebe and S Siedentopf and S Blaschke and D Schindele and M Porsch and D Baumunk and J J{\"u}rgens and F Fischbach and J Ricke and M Schostak and M B{\"o}hm and Liehr, {U B}",
year = "2018",
month = mar,
doi = "10.1007/s00270-017-1795-x",
language = "English",
volume = "41",
pages = "466--476",
journal = "CARDIOVASC INTER RAD",
issn = "0174-1551",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study

AU - Wendler, J J

AU - Pech, M

AU - Köllermann, J

AU - Friebe, B

AU - Siedentopf, S

AU - Blaschke, S

AU - Schindele, D

AU - Porsch, M

AU - Baumunk, D

AU - Jürgens, J

AU - Fischbach, F

AU - Ricke, J

AU - Schostak, M

AU - Böhm, M

AU - Liehr, U B

PY - 2018/3

Y1 - 2018/3

N2 - PURPOSE: Irreversible electroporation (IRE) is a new potential ablation modality for small renal masses. Animal experiments have shown preservation of the urine-collecting system (UCS). The purpose of this clinical study was to perform the first evaluation and comparison of IRE's effects on the renal UCS by using urinary cytology, magnetic-resonance imaging, and resection histology in men after IRE of pT1a renal-cell carcinoma (RCC).METHODS: Seven patients with biopsy-proven RCC pT1a cN0cM0 underwent IRE in a phase 2a pilot ablate-and-resect study (IRENE trial). A contrast-enhanced, diffusion-weighted MRI and urinary cytology was performed 1 day before and 2, 7, and 27 days after IRE. Twenty-eight days after IRE the tumour region was completely resected surgically.RESULTS: Technical feasibility was demonstrated in all patients. In all cases, MRI revealed complete coverage of the tumour area by the ablation zone with degenerative change. The urographic late venous MRI phase (urogram scans) demonstrated normal morphological appearances. Urine cytology showed a temporary vacuolisation of the cyto- and caryoplasmas after IRE. Whereas the urothelium showed signs of regeneration 28 days after IRE-ablation, the tumour and parenchyma below it showed necrosis and permanent tissue destruction.CONCLUSIONS: Renal percutaneous IRE appears to be a safe treatment for pT1a RCC. The preservation of the UCS with unaltered normal morphology as well as urothelial regeneration and a phenomenon (new in urinary cytology) of temporary degeneration with vacuolisation of detached transitional epithelium cells were demonstrated in this clinical pilot study.

AB - PURPOSE: Irreversible electroporation (IRE) is a new potential ablation modality for small renal masses. Animal experiments have shown preservation of the urine-collecting system (UCS). The purpose of this clinical study was to perform the first evaluation and comparison of IRE's effects on the renal UCS by using urinary cytology, magnetic-resonance imaging, and resection histology in men after IRE of pT1a renal-cell carcinoma (RCC).METHODS: Seven patients with biopsy-proven RCC pT1a cN0cM0 underwent IRE in a phase 2a pilot ablate-and-resect study (IRENE trial). A contrast-enhanced, diffusion-weighted MRI and urinary cytology was performed 1 day before and 2, 7, and 27 days after IRE. Twenty-eight days after IRE the tumour region was completely resected surgically.RESULTS: Technical feasibility was demonstrated in all patients. In all cases, MRI revealed complete coverage of the tumour area by the ablation zone with degenerative change. The urographic late venous MRI phase (urogram scans) demonstrated normal morphological appearances. Urine cytology showed a temporary vacuolisation of the cyto- and caryoplasmas after IRE. Whereas the urothelium showed signs of regeneration 28 days after IRE-ablation, the tumour and parenchyma below it showed necrosis and permanent tissue destruction.CONCLUSIONS: Renal percutaneous IRE appears to be a safe treatment for pT1a RCC. The preservation of the UCS with unaltered normal morphology as well as urothelial regeneration and a phenomenon (new in urinary cytology) of temporary degeneration with vacuolisation of detached transitional epithelium cells were demonstrated in this clinical pilot study.

KW - Journal Article

U2 - 10.1007/s00270-017-1795-x

DO - 10.1007/s00270-017-1795-x

M3 - SCORING: Journal article

C2 - 28929209

VL - 41

SP - 466

EP - 476

JO - CARDIOVASC INTER RAD

JF - CARDIOVASC INTER RAD

SN - 0174-1551

IS - 3

ER -